Nerre Therapeutics Ltd is an active company incorporated on 19 January 2012 with the registered office located in Stevenage, Hertfordshire. Nerre Therapeutics Ltd was registered 13 years ago.
NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin (NK)-1 receptor antagonist, for the treatment of chronic cough hypersensitivity disorders, particularly in patients with idiopathic pulmonary fibrosis (IPF).
Financials
Net Assets, Total Assets & Total Liabilities (2017–2024)